Navigation Links
Tabyat Partners, LLC. Launches iluvmydoc.com™, to Better Connect Patients with Doctors
Date:7/29/2009

New health care Web community offers doctors and individuals the ability to interact, manage and share

Skokie, Ill. (Vocus) July 29, 2009 -- Tabyat Partners, LLC. (www.tabyat.com), a health care technology company, is proud to announce the Beta launch, in Illinois, of its Web-based communication portal iluvmydoc.com™ (www.iluvmydoc.com). The site offers interactive services to doctors and individuals interested in actively participating in their health care management. Through iluvmydoc™ ("I Love My Doc"), doctors can create a customized doctor profile and purchase such Web-based services as online appointment requests and secure messaging services. Individuals can create, manage and share their personal health record (PHR) with doctors who have purchased iluvmydoc™ premium services.

In light of the rising costs of health care, the founders of Tabyat Partners want to help consumers become more active participants in their health care management and are seeking doctors that would like to add online services to their practice offering. By providing unique services to doctors and individuals, iluvmydoc™ aims to meet the needs of the current health care marketplace and enhance doctor-patient relationships. Tabyat Partners envisions iluvmydoc™ supporting the flow of health information in a secure and cost effective manner.

Co-Founder, Mr. Vinod Gidwani who has more than 35 years experience working with doctors in Illinois says, "The goal of iluvmydoc.com is to empower doctors online and give individuals the ability to take control in
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2

Related medicine news :

1. Health and Wellness Partners, Inc., A Wholly Owned Subsidiary of Zealous Inc., Launches Organix+
2. Wound Management Technologies, Inc. Announces Agreement with QX Partners, LLC
3. Audet & Partners, LLP Files First Raptiva Lawsuit After Announced Withdrawal
4. Health and Wellness Partners, Inc., a Wholly Owned Subsidiary of Zealous Inc., is Awarded the Exclusive California Distribution Rights for RockHard Weekend!!!
5. Energy Partners, LTD Shareholders At Risk
6. New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services
7. Former Genworth and GE Long Term Care Insurance Leader Brings Unique Sales Expertise to LTC Financial Partners, LLC
8. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
9. Healthcare Provider, HealthCare Partners, CEO Dr. Robert Margolis Honored for Hospital Philanthropy
10. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
11. Croft & Bender Advises Atlanta-based Alliance Surgery, Inc. in Its Acquisition by HealthMark Partners, Inc. of Nashville
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tabyat Partners, LLC. Launches iluvmydoc.com™, to Better Connect Patients with Doctors 
Tabyat Partners, LLC. Launches iluvmydoc.com™, to Better Connect Patients with Doctors
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Millions Flowing into Medical Real Estate 13292 1Millions Flowing into Medical Real Estate 13292 2Millions Flowing into Medical Real Estate 13292 3Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 1Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 2